ADMA Biologics, Inc. (NASDAQ:ADMA) Sees Large Growth in Short Interest

ADMA Biologics, Inc. (NASDAQ:ADMA - Get Free Report) was the recipient of a large increase in short interest in January. As of January 15th, there was short interest totalling 13,620,000 shares, an increase of 11.8% from the December 31st total of 12,180,000 shares. Based on an average trading volume of 3,500,000 shares, the days-to-cover ratio is presently 3.9 days.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on ADMA shares. Raymond James boosted their price target on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a "strong-buy" rating in a report on Friday, November 8th. HC Wainwright increased their target price on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a "buy" rating in a research report on Friday, November 8th.

Insider Transactions at ADMA Biologics

In related news, CFO Brad L. Tade sold 15,000 shares of ADMA Biologics stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $21.15, for a total transaction of $317,250.00. Following the sale, the chief financial officer now directly owns 199,433 shares in the company, valued at approximately $4,218,007.95. This trade represents a 7.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 3.70% of the company's stock.

Institutional Trading of ADMA Biologics

A number of large investors have recently modified their holdings of ADMA. Healthcare of Ontario Pension Plan Trust Fund boosted its stake in ADMA Biologics by 13.9% in the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 658,900 shares of the biotechnology company's stock worth $13,171,000 after buying an additional 80,400 shares in the last quarter. Assenagon Asset Management S.A. grew its holdings in shares of ADMA Biologics by 2.7% during the 3rd quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company's stock valued at $69,454,000 after purchasing an additional 92,281 shares during the last quarter. Lord Abbett & CO. LLC purchased a new position in ADMA Biologics in the 3rd quarter worth $61,858,000. EWG Elevate Inc. bought a new stake in ADMA Biologics in the fourth quarter worth $480,000. Finally, Citigroup Inc. boosted its position in ADMA Biologics by 251.7% during the third quarter. Citigroup Inc. now owns 387,226 shares of the biotechnology company's stock valued at $7,741,000 after buying an additional 277,138 shares during the period. Institutional investors own 75.68% of the company's stock.

ADMA Biologics Stock Performance

NASDAQ:ADMA traded up $0.13 on Tuesday, reaching $16.60. 1,210,374 shares of the company's stock were exchanged, compared to its average volume of 2,440,032. The firm has a market cap of $3.92 billion, a price-to-earnings ratio of 59.20 and a beta of 0.75. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The stock has a fifty day simple moving average of $18.10 and a 200-day simple moving average of $17.61. ADMA Biologics has a 52 week low of $5.02 and a 52 week high of $23.64.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.13 by $0.02. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The business had revenue of $119.84 million for the quarter, compared to analysts' expectations of $107.25 million. During the same quarter in the prior year, the firm posted $0.01 EPS. As a group, sell-side analysts predict that ADMA Biologics will post 0.51 earnings per share for the current year.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.